Suven Life Sciences Ltd
Suven Life Sciences Ltd (SUVEN)

Suven Life Sciences Ltd (SUVEN)

₹71.050.85%

Key Stats

₹70.3
Day's Price Range
₹71.7
₹60.8
52-Week Price Range
₹124.45
1 Month Return-1.27 %
3 Month Return0 %
1 Year Return-24.54 %

Company Financials

  • Quarterly
  • Annual
Value in ₹ crore

Peer Comparsion

PE
Rank 276
-9.25
EPS
Rank 283
₹-7.63
BVPS
Rank 286
₹6.61
Dividend Yield
Rank 176
ROE
Rank 629
-8.26%
Price To Book Ratio
10.65
Debt To Asset
Rank 295
0.15

Company Information

Suven Life Sciences Limited erstwhile Suven Pharmaceuticals SPL is in the business of Contract Research And Manufacturing Services CRAMS catering to the needs of global life science industry and fine chemical majors. Suvens CRAMS provide innovative process research and development supplies to clinical trials rapid response pilot scale manufacture dedicated commercial manufacturing on an exclusive basis. The company services include Custom Synthesis Process RD Scale Up and Contract Manufacturing of intermediates APIs and formulations. Suven Life Sciences has graduated from contract research to Collaborative Research transitioning from projectbased transactions into relationshipbased business. The Company has two international wholly owned subsidiary companies and one Indian wholly owned subsidiary company as on 31st March 2019. Suven Life Sciences Limited began operations in 1989 as specialty chemicals provider. Incorporated in Mar.89 as a private limited company Suven Pharmaceuticals SPL was converted into a public limited company in Jan.95. It was promoted by Sudharani Jasti and Venkateswarlu Jasti who is the present Chairman CEO of the company. In March 1995 SPL came out with a public issue of 9.8 lac equity shares at a premium of Rs 40 aggregating Rs 4.9 cr to partfinance the companys project for the manufacture of bulk drugs and drug intermediates and meet longterm working capital requirements totalling to Rs 6.43 cr. During 19992000 the company has acquired a small pilot plant in Jeedimetla Industrial Estate Hyderabad.During 200001 the company has registered a most remarkable record. The total sales of the company during 200001 have registered a growth of 71 over the previous year. The Profit After Tax PAT has also registered a growth of 325 over the previous year.The company has successfully achieved the recertification of ISO 9002 during the year 200001.During the financial year ended 31 March 2014 Suvens Drug discovery portfolio has expanded into several new therapeutic areas such as Major Depressive Disorder MDD Obesity and Pain through Neuronal Nicotinic Receptor modulators. In addition D4010 and G3031 are undergoing regulatory toxicological studies in preparation for them being moving into Phase 1 clinical trial during 201415.During the year 2014 Suven has made significant inroads into drug discovery with a specialization on CNSbased programmes targeting unmet medical needs. The Company enjoys a unique position in the India and Asia as one of the prominent company with technologies under central nervous system CNS. It has funded drug discovery for nine years resulting in a robust pipeline of 14 molecules at various stages of development. Suvens discovery assets address niche therapeutic areas like cognition depression obesity and pain management.In FY14 the Company filed one ANDA with the USFDA authorities for Malathion lotion a headlice product with sales potential estimated at US35 million. In 201314 it granted the exclusive license to Taro Pharmaceuticals to market the product in the US Canada and Mexico which is expected to generate revenues and royalty in 201415. During FY2015 Suvens lead clinical candidate SUVN502 has successfully completed Phase 1b clinical trial thus paving the way for the copound to move into Proof of Concept PoC Phase 2a study. In addition to above compounds SUVN D4010 is in its final stages of completing regulatory toxicological studies which will enable it to move into Phase 1 clinical trial in USA.During the FY2015 the Company has issued and allotted 10453690 equity shares of Re 1/ each at a premium of Rs 190.32 per share by way of QIP Issue in accordance with the SEBI ICDR guidelines.During FY15 the Companys main focus stayed on discovering developing and commercializing novel pharmaceutical products which are first in class or best in class CNS therapies through the use of GPCR targets. During FY15 the Company added two new clients to its CRAMS business. It commenced operations at its Vishakhapatnam unit and shifted the manufacturing intermediates for a specialty chemical product to this unit. The shift not only optimized capacities at its CRAMS facilities but also made the CRAMS operations more efficient.During FY2017 the company has spent Rs. 6973 lakhs on innovative RD in CNS therapies accounting for 13 on sales. Its focus remained on discovering developing and commercializing novel pharmaceutical products which are first in class CNS therapies through use of GPCR targets. During FY 2017 the Company has invested a sum of Rs 6501 lakhs in Suven Neurosciences Inc. a wholly owned subsidiary for its business purpose.In FY2018 the company has spent Rs 6390 lakhs on innovative RD in CNS therapies accounting for 10 on sales.During the year 2019 subject to approval of NCLT and other stakeholders the Companys Board considered and decided that the Company shall demerge CRAMS undertaking on a going concern basis to its wholly owned subsidiary Suven Pharmaceuticals Limited SPL through a Scheme of Arrangement between SLSL and SPL keeping in view the expected growth prospects in both CRAMS and discovery business which shall not only enable both the businesses to grow independently with their focused vision strategies and operations but also contribute significantly towards unlocking the potential value of the businesses for the shareholders. The consideration for demerger shall be issue of 1 fully paid up equity share of face value of Re 1/ each of SPL for every 1 fully paid up equity share of face value of Re 1/ each held by each shareholder in the Demerged Company SLSL as on the Record Date thereby resulting in a mirror shareholding of SLSL in SPL.The Company invested a sum of Rs.13636 lakhs in Suven Neurosciences Inc. for its business purpose. The Company acquired entire share capital of Rs.1 lakh in Suven Pharmaceuticals Limited identified as Resulting Company for the purpose of Scheme of Arrangement Demerger and as of 31st March 2019 no investments were made in newly formed Suven Pharma Inc. in USA.During the FY 20182019 Suven Pharmaceuticals Limited in India and Suven Pharma Inc. in USA have become subsidiary companies.
OrganisationSuven Life Sciences Ltd
HeadquartersHyderabad
IndustryPharmaceuticals